目的 探讨本中心达妥昔单抗β治疗神经母细胞瘤患儿的临床反应及安全性。方法 回顾性分析13例2022年以来接受达妥昔单抗β免疫治疗的儿童神经母细胞瘤患儿，总结并分析治疗中出现的不良反应，评估治疗过程的安全性及患儿的耐受性。结果 达妥昔单抗β治疗过程中主要有发热、疼痛、胃肠道反应（腹泻/恶心/呕吐）、毛细血管渗漏综合征、眼毒性、支气管痉挛、皮疹、血液学毒性及感染等不良反应，基本都是3级及以下的不良反应，通过一些常见药物的对症治疗或调整达妥昔单抗β的输注速度后均能得到有效的缓解，安全性较高；患者随着治疗周期推进，各种不良反应发生率下降，对治疗的耐受性较好。结论 应用达妥昔单抗β治疗儿童神经母细胞瘤具有良好的安全性和耐受性，随着治疗周期的增加，不良反应逐步减少甚至消失。

Objective To investigate the clinical response and security of dinutuximab β immunotherapy in neuroblastoma children. Methods A retrospective analysis was performed on 13 children who received dinutuximab β immunotherapy in our hospital since 2022 to evaluate the adverse reactions, tolerability, safety and short-term efficacy during treatment. Result During the treatment of dinutuximab β, the main adverse reactions were fever, pain, gastrointestinal reactions (diarrhea/nausea/vomiting), capillary leakage syndrome, ocular toxicity, bronchospasm, rash, hematological toxicity and infection, which were basically grade 3 and below. After symptomatic treatment with some common drugs or adjustment of the infusion rate of dinutuximab β, it can be effectively alleviated with high security. With the advance of treatment cycle, the incidence of various side effects decreased, and the patients had a good tolerance to treatment. Conclusion The use of dinutuximab β immunotherapy for pediatric neuroblastoma has good safety and tolerability, and the adverse reactions gradually decrease or disappear with the increase of treatment cycle.